News of additional positive data from three phase III trials for Anoro Ellipta (umeclidinium/vilanterol), the first FDA-approved combo long-acting beta2-adrenergic agonist (LABA)/long-acting muscarinic antagonist (LAMA), generated little buzz for Theravance Inc., though it adds further ammunition as partner Glaxosmithkline plc fights to maintain its hold on the respiratory disease market in the face of generic threats to its top-selling Advair/Seretide franchise.